Posts in BBLSA WP Feature
The Radiopharmaceutical Renaissance: Radiating Hope in Medicine

The year 2022 was a watershed year for the radiopharmaceuticals space with 25 strategic transactions and $527M invested from the VC community. Despite an overall downturn in the biotech market in the 2022-2023 timeframe, the strategic and VC activity within the radiopharmaceutical space has remained relatively strong. Indeed, the average raise for radiopharma sponsors in 2023 was $51M, which eclipsed that of 2022, $38M.

Read More
A Culture of Success – Emerging Trends in Cell Technology

The ability to facilitate the growth and expansion of mammalian cells in vitro has been at the backbone of a wave of therapeutic innovations in the biotech space. Increasingly the know-how, materials, and equipment to harness cells as factories to produce complex proteins for therapeutic uses is being directed toward consumer applications. 

Read More
Vision of Commercial Success: Investment and Partnering Landscape for Psychedelics

A growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).

Read More
Microbiome Medicinal Products: Concept to Commercial

A growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).

Read More
Roaring 20s Redux: The Next Decade of Gene Therapy Innovation

Over the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for the genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. However, as the first gene therapies began to post early wins, several technical and commercial challenges emerged.

Read More
The NASH Dash: Analysis Of The Non-Alcoholic Steatohepatitis (NASH) Drug Pipeline & Market

Over the last decade, NASH has remained a graveyard for drug development. To date, there are no disease-specific approved therapies on the market. Companies in the dash for a NASH breakthrough may require strategic repositioning to maximize asset value in the near-term. In our latest white paper, Back Bay Life Science Advisors analyzed the opportunities and challenges ahead for companies seeking a NASH breakthrough.

Read More
The ABC's of Oncology: Looking Beyond Alpha-Beta Cells for Cell Therapies

Cell therapies for cancer, particularly chimeric antigen receptor (CAR)-modified αβ T cells, have rapidly proven their utility. However, as limitations of these therapies have become clearer, interest in alternative approaches has grown. A second generation of companies built on several scientific discoveries is advancing cell therapies of the innate immune system (such as γδ T and NK cells) to address the limitations of CAR T-cell therapies…

Read More
A Gutsy Combination: The Microbiome and Immuno-oncology

With a growing body of pre-clinical and clinical research, the influence of bacteria on human health and disease has emerged from the shadows and into the limelight. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”), has a profound influence on maintaining normal physiologic function…

Read More